Shima Y, Yoshida H, Suminaga K, Yoshida H, Hashimoto K, Ogimoto T
BMC Cancer. 2025; 25(1):388.
PMID: 40038680
PMC: 11877893.
DOI: 10.1186/s12885-025-13785-x.
Kim D, Lee J, Toyama T, Liyanage T, Woodward M, Matsushita K
Nephrology (Carlton). 2025; 30(2):e70002.
PMID: 39888116
PMC: 11780214.
DOI: 10.1111/nep.70002.
Haase V, Tanaka T, Koury M
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):409-418.
PMID: 39644030
PMC: 11665514.
DOI: 10.1182/hematology.2024000655.
Bertrand A, Lewis A, Camps J, Grau V, Rodriguez B
Cardiovasc Diabetol. 2024; 23(1):371.
PMID: 39427200
PMC: 11491016.
DOI: 10.1186/s12933-024-02465-y.
Nyma Z, Kitaoka K, Yano Y, Kanegae H, Bayaraa N, Kishi S
Sci Rep. 2024; 14(1):11481.
PMID: 38769367
PMC: 11106300.
DOI: 10.1038/s41598-024-62152-6.
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.
Tanaka H, Tani A, Onoda T, Ishii T
In Vivo. 2024; 38(2):917-922.
PMID: 38418113
PMC: 10905430.
DOI: 10.21873/invivo.13519.
Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha.
Khullar D, Muchhala S, T A
Cureus. 2024; 16(1):e51613.
PMID: 38313992
PMC: 10837100.
DOI: 10.7759/cureus.51613.
The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Zhou Q, Mao M, Li J, Deng F
Ren Fail. 2023; 45(1):2195011.
PMID: 37489561
PMC: 10392337.
DOI: 10.1080/0886022X.2023.2195011.
Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.
Zhao X, Liu S, Wang Z, Zhang S, You L
Eur J Med Res. 2023; 28(1):230.
PMID: 37430374
PMC: 10331997.
DOI: 10.1186/s40001-023-01179-3.
Association of Community Water Lead Levels and Erythropoietin Stimulating Agent Use among End-Stage Kidney Disease Patients.
Danziger J, Dodge L, Mukamal K
Environ Health Perspect. 2022; 130(12):127703.
PMID: 36542478
PMC: 9770039.
DOI: 10.1289/EHP10815.
Effect of roxadustat on serum metabolome and lipidome in patients with end-stage renal disease and erythropoiesis-stimulating agent resistance.
Wang L, Wu Y, Li Y, You L, Liu X, Wang Z
Ann Transl Med. 2022; 10(19):1069.
PMID: 36330384
PMC: 9622472.
DOI: 10.21037/atm-22-4451.
Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
Zhang L, Gan L, Li K, Xie P, Tan Y, Wei G
Eur J Clin Pharmacol. 2022; 78(9):1421-1434.
PMID: 35711066
PMC: 9365747.
DOI: 10.1007/s00228-022-03328-9.
Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease.
Wu H, Chinnadurai R
Kidney Dis (Basel). 2022; 8(2):103-114.
PMID: 35527989
PMC: 9021651.
DOI: 10.1159/000521162.
Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases.
Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoch K
Nutrients. 2022; 14(5).
PMID: 35268014
PMC: 8912638.
DOI: 10.3390/nu14051039.
Efficacy and safety of recombinant human erythropoietin (Hema-Plus) for management of anemia in Thai patients on peritoneal dialysis.
Chuengsaman P, Narenpitak S, Sritippayawan S
World J Nephrol. 2021; 10(6):109-121.
PMID: 34909408
PMC: 8641037.
DOI: 10.5527/wjn.v10.i6.109.
Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Munie S, Pintavorn P
Case Rep Nephrol Dial. 2021; 11(2):167-175.
PMID: 34327219
PMC: 8299384.
DOI: 10.1159/000512612.
Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M, Zhu C, Yan T, Zhou Y, Lv Q, Chuan J
Front Pharmacol. 2021; 12:658079.
PMID: 34276361
PMC: 8283176.
DOI: 10.3389/fphar.2021.658079.
Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial.
Kawai Y, Toya Y, Wakui H, Fujikawa T, Ueda E, Azushima K
J Clin Hypertens (Greenwich). 2021; 23(4):870-878.
PMID: 33481341
PMC: 8678717.
DOI: 10.1111/jch.14171.
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Pergola P, Devalaraja M, Fishbane S, Chonchol M, Mathur V, Smith M
J Am Soc Nephrol. 2020; 32(1):211-222.
PMID: 33272965
PMC: 7894678.
DOI: 10.1681/ASN.2020050595.
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan.
Hayashi T, Kato H, Tanabe K, Nangaku M, Hirakata H, Wada T
Clin Exp Nephrol. 2020; 25(2):110-119.
PMID: 32949295
PMC: 7880978.
DOI: 10.1007/s10157-020-01969-7.
